Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Thrombosis Research Année : 2024

Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?

Christine Mouton
  • Fonction : Auteur
Emmanuel De Maistre

Résumé

Given the growing number of patients receiving direct oral anticoagulant (DOAC), patients requiring rapid neutralization is also increasing in case of major bleedings or urgent surgery/procedures. Idarucizumab is commercialized as a specific antidote to dabigatran while andexanet alfa has gained the Food and Drug Administration and the European Medicines Agency approval as an oral anti-factor Xa inhibitors antidote. Other antidotes or hemostatic agents are still under preclinical or clinical development, the most advanced being ciraparantag. DOAC plasma levels measurement allows to appropriately select patient for antidote administration and may prevent unnecessary prescription of expensive molecules in some acute clinical settings. However, these tests might be inconclusive after some antidote administration, namely andexanet alfa and ciraparantag. The benefit of laboratory monitoring following DOAC reversal remains unclear. Here, we sought to provide an overview of the key studies evaluating the safety and efficacy of DOAC reversal using the most developed/commercialized specific antidotes, to discuss the potential role of the laboratory monitoring in the management of patients receiving DOAC specific antidotes and to highlight the areas that deserve further investigations in order to establish the exact role of laboratory monitoring in the appropriate management of DOAC specific antidotes.
Fichier principal
Vignette du fichier
Is there a role for the laboratory monitoring in the management of specific.pdf (1.42 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

hal-04567586 , version 1 (16-05-2024)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Nicolas Gendron, Paul Billoir, Virginie Siguret, Véronique Le Cam Duchez, Valerie Proulle, et al.. Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?. Thrombosis Research, 2024, 237, pp.171-180. ⟨10.1016/j.thromres.2024.04.005⟩. ⟨hal-04567586⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More